Sensus Healthcare (NASDAQ:SRTS) Share Price Crosses Above 50-Day Moving Average – What’s Next?

Sensus Healthcare, Inc. (NASDAQ:SRTS)’s stock price crossed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $2.92 and traded as high as $2.98. Sensus Healthcare shares last traded at $2.98, with a volume of 10,982 shares trading hands.

Analyst Ratings Changes

A number of research analysts recently issued reports on SRTS shares. Weiss Ratings restated a “sell (d)” rating on shares of Sensus Healthcare in a report on Friday, July 17th. Citigroup reiterated a “buy” rating on shares of Sensus Healthcare in a report on Friday, May 8th. Finally, Wall Street Zen lowered Sensus Healthcare from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 9th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $6.88.

Sensus Healthcare Trading Up 1.4%

The business’s 50 day moving average price is $2.92 and its two-hundred day moving average price is $3.72. The stock has a market cap of $49.05 million, a P/E ratio of -6.34 and a beta of 1.10.

Sensus Healthcare (NASDAQ:SRTS) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.04). The company had revenue of $3.39 million during the quarter, compared to the consensus estimate of $5.32 million. Sensus Healthcare had a negative return on equity of 15.79% and a negative net margin of 34.50%.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. XTX Topco Ltd bought a new stake in shares of Sensus Healthcare during the fourth quarter valued at approximately $77,000. Jane Street Group LLC purchased a new stake in Sensus Healthcare in the fourth quarter worth $79,000. Ingalls & Snyder LLC bought a new position in Sensus Healthcare in the fourth quarter worth $219,000. State Street Corp raised its holdings in Sensus Healthcare by 5.2% in the fourth quarter. State Street Corp now owns 69,252 shares of the company’s stock worth $276,000 after purchasing an additional 3,400 shares in the last quarter. Finally, Bank of New York Mellon Corp purchased a new position in Sensus Healthcare during the second quarter valued at $303,000. Institutional investors own 25.30% of the company’s stock.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.